SCHEMBL642233

SCHEMBL642233

Nc1ccccc1-c1cc(Cl)ccc1S

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
S100A4 P26447 1/20 0.41
IDO1 P14902 4/20 0.41
TSHR P16473 4/20 0.40
CYP3A4 P08684 4/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
ALOX15 P16050 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
HSD17B10 Q99714 2/20 0.39
TP53 P04637 1/20 0.39
RECQL P46063 1/20 0.39
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
GFER P55789 1/20 0.37
KMT2A Q03164 1/20 0.37
HPGD P15428 1/20 0.36
ALOX12 P18054 1/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL398356 0.80 ALDH1A1 (0.54) ALDH1A1L3MBTL1S100A4IDO1TSHR
SCHEMBL29282857 0.77 S100A4 (0.41) ALDH1A1L3MBTL1S100A4TSHRSMN1; SMN2
SCHEMBL1269994 0.77 ALDH1A1 (0.68) ALDH1A1L3MBTL1IDO1TSHRCYP3A4
SCHEMBL397076 0.76 ALDH1A1 (0.54) ALDH1A1L3MBTL1S100A4TSHRCYP3A4
SCHEMBL642232 0.76 PDE7A (0.49) ALDH1A1L3MBTL1S100A4IDO1TSHR
SCHEMBL29154513 0.74 ALDH1A1 (0.65) ALDH1A1L3MBTL1IDO1TSHRCYP3A4
SCHEMBL31403273 0.74 ALDH1A1 (0.65) ALDH1A1L3MBTL1IDO1TSHRCYP3A4
SCHEMBL11618272 0.74 CYP1A2 (0.46) ALDH1A1S100A4TSHRSMN1; SMN2ALOX15
SCHEMBL31122335 0.74 CYP1A2 (0.46) ALDH1A1S100A4TSHRSMN1; SMN2ALOX15
SCHEMBL30978223 0.73 CYP3A4 (0.50) ALDH1A1S100A4IDO1TSHRCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1960347-B1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 (17BETA-HSD3) INHIBITORS STERIX LTD (GB) 2012-06-20 EP disclosed
US-8119627-B2 Heterocyclic compounds as inhibitors of 17beta-HSD3 STERIX LIMITED (GB) 2012-02-21 US disclosed
US-20090023710-A1 Compound OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2009-01-22 US disclosed
EP-1960347-A2 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 (17BETA-HSD3) INHIBITORS Sterix Limited (GB) 2008-08-27 EP disclosed
WO-2007003934-A2 17BETA-HYDR0XYSTER0ID DEHYDROGENASE TYPE 3 (17BETA-HSD3 ) INHIBITORS STERIX LIMITED (GB) 2007-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023710-A1 Compound NR1H3, NR1H2, NR1H4 ALDH1A1 2109/4885L3MBTL1 2752/4885S100A4 3766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.